Ascendis Pharma, INC.
Based in CA
AI Overview
With $3.0M in lobbying spend across 23 quarterly filings, Ascendis Pharma, INC is a significant lobbying presence. Their lobbying covers 2 issue areas. Active from 2020 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $110K |
| 2021 | $500K |
| 2022 | $570K |
| 2023 | $590K |
| 2024 | $540K |
| 2025 | $650K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Ascendis Pharma, INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy
Food and Drug Administration, Orphan Drugs
Rare disease issues. Orphan drugs. Prescription Drug User Fee (PDUFA) reauthorization. Biosimilar User Fee Act (BsUFA) reauthorization. Food and Drug Administration facility inspections.
Rare disease issues. Orphan drugs. Prescription Drug User Fee (PDUFA) reauthorization. Biosimilar User Fee Act (BsUFA) reauthorization. Cancer research.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.